Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Opthea Ltd ADR
(NQ:
OPT
)
3.149
+0.019 (+0.59%)
Streaming Delayed Price
Updated: 10:01 AM EST, Nov 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Opthea Ltd ADR
Opthea to Receive US$35M Commitment and Additional US$50M Funding
December 27, 2023
From
Opthea Limited
Via
GlobeNewswire
Opthea Receives A$8.8 million R&D Tax Incentive
December 19, 2023
From
Opthea Limited
Via
GlobeNewswire
Opthea to Present at the FLORetina 2023 Congress
December 01, 2023
From
Opthea Limited
Via
GlobeNewswire
Opthea to Present at the Jefferies 2023 London Healthcare Conference
November 09, 2023
From
Opthea Limited
Via
GlobeNewswire
Opthea to Present at Eyecelerator Forum at the 2023 American Academy of Ophthalmology (AAO) Conference
October 30, 2023
From
Opthea Limited
Via
GlobeNewswire
Opthea Appoints U.S.-Based Leadership with Fred Guerard as CEO and Peter Lang as CFO
October 27, 2023
From
Opthea Limited
Via
GlobeNewswire
Opthea to Participate at the 2023 Euretina Congress
October 02, 2023
From
Opthea Limited
Via
GlobeNewswire
Opthea to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 07, 2023
From
Opthea Limited
Via
GlobeNewswire
Opthea Successfully Completes Institutional Offer and Increases Capital Raising to A$90.0m (US$57.6 million¹)
August 28, 2023
From
Opthea Limited
Via
GlobeNewswire
Opthea Announces “Sozinibercept” as the Nonproprietary Drug Name for OPT-302
July 26, 2023
From
Opthea Limited
Via
GlobeNewswire
Opthea to Present at the 2023 Ophthalmology Innovation Summit
July 24, 2023
From
Opthea Limited
Via
GlobeNewswire
Opthea to Feature at the American Society of Retina Specialists 2023 Annual Meeting
July 13, 2023
From
Opthea Limited
Via
GlobeNewswire
Opthea Announces Departure of Chief Medical Officer and Appointment of Senior Medical Advisor
July 10, 2023
From
Opthea Limited
Via
GlobeNewswire
Opthea Appoints Anshul Thakral as Non-Executive Director of the Board
June 08, 2023
From
Opthea Limited
Via
GlobeNewswire
Opthea to Present at the Jefferies 2023 Healthcare Conference
May 25, 2023
From
Opthea Limited
Via
GlobeNewswire
Opthea to Participate in EF Hutton Hosted Discussion on OPT-302 and the Wet AMD Market
May 17, 2023
From
Opthea Limited
Via
GlobeNewswire
Opthea To Present at the JMP Securities Life Sciences Conference
May 08, 2023
From
Opthea Limited
Via
GlobeNewswire
Opthea To Participate at the H.C. Wainwright BioConnect Conference at NASDAQ
April 28, 2023
From
Opthea Limited
Via
GlobeNewswire
Opthea Receives A$8.7 million R&D Tax Incentive
March 07, 2023
From
Opthea Limited
Via
GlobeNewswire
Opthea To Participate in Fireside Chat at Oppenheimer’s 33rd Annual Healthcare Conference
March 06, 2023
From
Opthea Limited
Via
GlobeNewswire
Opthea Phase 2b Trial Results of OPT-302 in Combination with Lucentis® for wet AMD Published in the Journal Ophthalmology
February 13, 2023
From
Opthea Limited
Via
GlobeNewswire
Opthea To Present at SVB Leerink Global Biopharma Conference
February 06, 2023
From
Opthea Limited
Via
GlobeNewswire
Opthea To Present at Sequire Biotechnology Conference
January 30, 2023
From
Opthea Limited
Via
GlobeNewswire
Opthea Announce MST Access Hosted Conference Call with Professor Jason S. Slakter, MD
December 12, 2022
From
Opthea Limited
Via
GlobeNewswire
Opthea to Present at the FLORetina 2022 Congress
December 06, 2022
From
Opthea Limited
Via
GlobeNewswire
Opthea to Present at Jefferies London Healthcare Conference
November 10, 2022
From
Opthea Limited
Via
GlobeNewswire
Opthea Expands Leadership Team with the Appointment of Timothy E. Morris as Chief Financial Officer
October 24, 2022
From
Opthea Limited
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.